ONCAlert | 2018 ASCO Annual Meeting

Results for Niraparib Maintenance Therapy for Patients With Ovarian Cancer

Ursula A. Matulonis, MD
Published Online: 6:36 PM, Tue March 14, 2017

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer. The results of the study demonstrated an improvement in the median progression-free survival for patients who received niraparib versus placebo. 

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.